INDV vs SYK: fair value comparison
Indivior Pharmaceuticals, Inc. and Stryker Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SYK currently sits closer to the top of our discount ranking. SYK carries the stronger quality grade.
| INDV | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $37.37 | $330.69 |
| 12-month range | $23.46–$40.25 | $294.73–$389.94 |
| Sector rank | #29 of 113 Healthcare | #24 of 113 Healthcare |
| Quality grade | F | A |
| Momentum grade | — | C |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: INDV fair value analysis · SYK fair value analysis